Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy

Supportive Care in Cancer

Volumn 11, Issue 8, 2003, Pages 516-521

  Treish, Imad ^a   Shord, Stacy ^a   Valgus, John ^a   Harvey, Donald ^a   Nagy, Jessica ^a   Stegal, Jennifer ^a   Lindley, Celeste ^a,b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Acupressure; Acustimulation; Chemotherapy; Nausea; Reliefband; Transcutaneous electrical stimulation; Vomiting

Indexed keywords

ADJUVANT THERAPY; ADULT; ANTIEMETIC ACTIVITY; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL LIVING INDEX EMESIS; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; STATISTICAL ANALYSIS; TRANSCUTANEOUS NERVE STIMULATION; VOMITING; WILCOXON SIGNED RANKS TEST;

ADULT; ANTIEMETICS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PLACEBOS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VOMITING;

EID: 0043011239     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-003-0467-3     Document Type: Article

References (32)

1. Abang AM, Takemoto MH, Pham T, Mandanas RA, Roy V, Selby GB, et al (2000) Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation. Anticancer Drugs 11:(2)137-142
2. Anonymous (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. Ann Oncol 6:805-810
3. Anonymous (1999) ASHP Therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Healthsystem Pharm 56:(8)729-764
4. Birch R, Weaver CH, Carson K, Buckner CD (1998) A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethosone in patients receiving high-dose cyclophosphamide, thiorepa and carboplatin. Bone 22:(7)685-8
5. Bshunow PW, Matteson SE, Morrow G, Roscoe J (2002) Patients with intractable chemotherapy-induced nausea find acustimulation band helpful. Procedings of the annual meeting, Am Soc Clin Oncol 22: Abstract
6. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 15 19:(6)1759-1767
7. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH et al (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835-842
8. Dundee JW. (1990) Belfast experience with P6 acupuncture antiemesis. Ulster Med J 59:63-70
9. Dundee JW, Ghaly RG, Fitzpatrick KT, Abram WP, Lynch GA. (1989) Acupuncture prophylaxis of cancer chemotherapy-induced sickness. J R Soc Med 82:268-271
10. Dundee JW, McMillan CM (1990) Clinical uses of P6 acupuncture antiemesis. Acupunct Electrother Res 15:211-215
11. Dundee JW, Yang J (1990) Prolongation of the antiemetic action of P6 acupuncture by acupressure in patients having cancer chemotherapy. J R Soc Med 83:360-362
12. Dundee JW, Yang J, Ghaly RG (1990) Vomiting and chemotherapy. Lancet 335:541
13. Dundee JW, Yang J, McMillan C (1991) Non-invasive stimulation of the P6 (Neiguan) antiemetic acupuncture point in cancer chemotherapy. J R Soc Med 84:210-212
14. Dranitsaris G, Leung P, Ciotti R, Ortega A, Spinthouri M, Liaropoulos L, et al (2001) A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. Pharmacoeconomics 19(9):955-67
15. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. [erratum appears in J Clin Oncol 1999 Dec; 17(12):3860; J Clin Oncol 2000 Aug;18(16):3064]. J Clin Oncol 17:2971-2994
16. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, et al (1996) On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Onc 7:(2)189-195
17. Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T (1996) Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4:(6)435-439
18. Herrington JD, Kwan P, Young RR, Lagow E, Lagrone L, Riggs MW (2000) Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy 20:1318-1323
19. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, et al (1999) Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis. J Clin Oncol 17:(1)338-343
20. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109
21. Pearson J, Blumentals W, Martin A, Carides A, Horgan K, Wittreich J, et al (2000) Validation of Functional Living Index-Emesis (FLIE) Quality-of-life questionnaire for acute and delayed chemotherapy-induced emesis. Proceedings of the annual meeting, Am Soc Clin Oncol 20:2384
22. Laszlo J (1983) Nausea and vomiting as major complications of cancer chemotherapy. Drugs [Suppl 1] 25:1-7
23. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
24. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials Group. New Eng J Med 340:(3)190-195
25. Orchard PJ, Rogosheske J, Burns L, Rydholm N, Larson H, DeFor TE, et al (1999) A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 5:(6)386-393
26. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of post-chemotherapy nausea and vomiting on health-related quality of life. The quality of life and symptom control committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5:(4)307-313
27. Osowski CL, Dix SP, Lynn M, Davidson T, Cohen L, Miyahara T, et al (1998) An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. Support Care Cancer 6:511-517
28. Oyama H, Kaneda M, Katsumata N, Akechi T, Ohsuga M. (2000) Using the bedside wellness system during chemotherapy decreases fatigue and emesis in cancer patients. J Med Syst 24:173-182
29. Pearl ML, Fischer M, McCauley DL, Valea FA, Chalas E. (1999) Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients. Cancer Nurs 22:307-311
30. Saller R, Hellenbrecht D, Buhring M, Hess H. (1986) Enhancement of the antiemetic action of metoclopramide against cisplatin-induced emesis by transdermal electrical nerve stimulation. J Clin Pharmacol 26:115-119
31. Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P (2001) Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Onc 19:(7)2091-2097
32. Vincent CA, Richardson PH (1986) The evaluation of therapeutic acupuncture: concepts and methods. Pain. 24:(1)1-13